|Amorphous silica nanoparticles aggregate human platelets: potential implications for vascular homeostasis.|
|Jump to Full Text|
|PMID: 22334785 Owner: NLM Status: MEDLINE|
|BACKGROUND: Amorphous silica nanoparticles (SiNP) can be used in medical technologies and other industries leading to human exposure. However, an increased number of studies indicate that this exposure may result in cardiovascular inflammation and damage. A high ratio of nitric oxide to peroxynitrite concentrations ([NO]/[ONOO(-)]) is crucial for cardiovascular homeostasis and platelet hemostasis. Therefore, we studied the influence of SiNP on the platelet [NO]/[ONOO(-)] balance and platelet aggregation.
METHODS: Nanoparticle-platelet interaction was examined using transmission electron microscopy. Electrochemical nanosensors were used to measure the levels of NO and ONOO(-) released by platelets upon nanoparticle stimulation. Platelet aggregation was studied using light aggregometry, flow cytometry, and phase contrast microscopy.
RESULTS: Amorphous SiNP induced NO release from platelets followed by a massive stimulation of ONOO(-) leading to an unfavorably low [NO]/[ONOO(-)] ratio. In addition, SiNP induced an upregulation of selectin P expression and glycoprotein IIb/IIIa activation on the platelet surface membrane, and led to platelet aggregation via adenosine diphosphate and matrix metalloproteinase 2-dependent mechanisms. Importantly, all the effects on platelet aggregation were inversely proportional to nanoparticle size.
CONCLUSIONS: The exposure of platelets to amorphous SiNP induces a critically low [NO]/[ONOO(-)] ratio leading to platelet aggregation. These findings provide new insights into the pharmacological profile of SiNP in platelets.
|J Jose Corbalan; Carlos Medina; Adam Jacoby; Tadeusz Malinski; Marek W Radomski|
Related Documents :
|2015815 - 3-aminobenzamide inhibits cytotoxicity and adhesion of phorbol-ester-stimulated granulo...
12864975 - Granulocyte macrophage colony stimulating factor (gm-csf) activity is regulated by a gm...
1372185 - Defective glycosylphosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglo...
7658075 - Activities of clarithromycin, azithromycin, and ofloxacin in combination with liposomal...
8610905 - The in vitro effects of phosphodiesterase inhibitors on the human internal mammary artery.
2015815 - 3-aminobenzamide inhibits cytotoxicity and adhesion of phorbol-ester-stimulated granulo...
|Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2012-02-07|
|Title: International journal of nanomedicine Volume: 7 ISSN: 1178-2013 ISO Abbreviation: Int J Nanomedicine Publication Date: 2012|
|Created Date: 2012-02-15 Completed Date: 2012-09-04 Revised Date: 2013-06-26|
Medline Journal Info:
|Nlm Unique ID: 101263847 Medline TA: Int J Nanomedicine Country: New Zealand|
|Languages: eng Pagination: 631-9 Citation Subset: IM|
|School of Pharmacy and Pharmaceutical Sciences, Faculty of Health Sciences, Panoz Institute, Trinity College Dublin, Ireland.|
|APA/MLA Format Download EndNote Download BibTex|
Analysis of Variance
Blood Platelets / cytology, drug effects*, metabolism
Nanoparticles / chemistry*, toxicity
Nitric Oxide / blood
Peroxynitrous Acid / blood
Platelet Aggregation / drug effects*
Silicon Dioxide / chemistry, pharmacology*
|10102-43-9/Nitric Oxide; 14691-52-2/Peroxynitrous Acid; 7631-86-9/Silicon Dioxide|
Journal ID (nlm-ta): Int J Nanomedicine
Publisher: Dove Medical Press
© 2012 Corbalan et al, publisher and licensee Dove Medical Press Ltd.
collection publication date: Year: 2012
Print publication date: Year: 2012
Electronic publication date: Day: 07 Month: 2 Year: 2012
Volume: 7First Page: 631 Last Page: 639
PubMed Id: 22334785
Publisher Id: ijn-7-631
|Amorphous silica nanoparticles aggregate human platelets: potential implications for vascular homeostasis|
|J Jose Corbalan12|
|Marek W Radomski1|
1School of Pharmacy and Pharmaceutical Sciences, Faculty of Health Sciences, Panoz Institute, Trinity College Dublin, Ireland
2Department of Chemistry and Biochemistry, Ohio University, Athens, OH, USA
|Correspondence: Correspondence: Carlos Medina, School of Pharmacy and Pharmaceutical Sciences, Faculty of Health Sciences, Panoz Institute, Trinity College Dublin, Dublin 2, Ireland, Tel +353 1 896 2823, Fax +353 1 896 3367, Email firstname.lastname@example.org
It is increasingly recognized that engineered amorphous silica nanoparticles (SiNP) may have important implications for vascular homeostasis. We have recently demonstrated the ability of SiNP to induce endothelial cell dysfunction linked to increased peroxynitrite (ONOO−) production.1 As human blood platelets along with endothelium play a critical role in vascular homeostasis, we have now examined the biocompatibility of amorphous SiNP (10 nm, 10SiNP; 50 nm, 50SiNP; 150 nm, 150SiNP; 500 nm, 500SiNP) with human platelets.
The vascular NO, synergistically with prostacyclin, inhibits platelet activation and aggregation.2–5 This vasorelaxant and platelet regulator is essential for vascular homeostasis and an impairment of NO bioavailability is one of the earliest events in vascular diseases.6,7 Superoxide anion reacts rapidly with NO producing ONOO−, a major component of oxidative stress, rapidly decreasing NO bioavailability.8 A high ONOO− production and depleted NO availability resulting in a low ratio of maximal NO to maximal ONOO− concentrations ([NO]/[ONOO−]) can be accurately used as an indicator of nitroxidative/oxidative stress and dysfunction of the cardiovascular system.1,9–11 The high [NO]/[ONOO−] balance is essential for maintaining platelet regulation, as high amounts of ONOO− counteract the platelet-inhibitory effects of NO leading to platelet activation and aggregation.12
In the current studies, a direct release of NO and ONOO− during nanoparticle-platelet interactions was measured electrochemically by nanosensors. The NO generation by platelets was followed by a greater ONOO− production leading to a low [NO]/[ONOO−] ratio. Indeed, we demonstrated that amorphous SiNP induced activation of the glycoprotein IIb/IIIa (GPIIb/IIIa) and expression of the selectin P (SELP) on the platelet surface membrane leading to platelet activation and aggregation. The activation of GPIIb/IIIa is triggered off by the release of major platelet activators that mediate pathways of aggregation such as thromboxane A2 (TXA2),13 adenosine diphosphate (ADP)14 and matrix metalloproteinase 2 (MMP2)15 which amplify aggregation. Our studies showed that SiNP induce platelet aggregation via stimulation of ADP and MMP2 released from platelets.
All reagents were purchased from Sigma-Aldrich (Arklow, Ireland) unless otherwise indicated. Engineered amorphous SiNP with different sizes (10 nm, 50 nm, 150 nm, and 500 nm) were purchased from Polysciences (Eppelheim, Germany).
The zeta potentials of all the SiNP were determined by a Zetasizer Nano ZS (Malvern Instruments, Malvern, UK). Measurements were performed six times for each particle size (100 μg/mL in ultrapure water) at room temperature.
Nanoparticle suspensions (10 μg/mL in ultrapure water) were examined by a JEM 2100 transmission electron microscope (JEOL, Herts, UK). The diameter of 100 nanoparticles of each size on three TEM micrographs was measured by ImageJ an open-source, Java-based imaging software (http://rsbweb.nih.gov/ij/).
Blood was obtained from healthy volunteers who had not taken any drugs known to affect platelet function for 2 weeks prior to the study. Washed platelets were obtained as described previously.16 Briefly, blood was collected and anticoagulated using trisodium citrate (3.15% w/v; 9:1 v/v). The citrated blood was centrifuged at room temperature to prepare platelet-rich plasma (PRP). Washed platelets were prepared by centrifugation of PRP, containing prostacyclin at room temperature. Following isolation, platelets were resuspended in prostacyclin-free Tyrode’s salt solution. Washed platelet concentrations were adjusted using Tyrode’s salt solution to a final concentration of 2.5 × 108 platelets per milliliter.
Immediately before use, commercial stock suspensions of SiNP were sonicated for 2 minutes and nanoparticle dispersions in Tyrode’s salt solution were prepared by serial dilution from these stock suspensions by vortexing. We tested the effect of different SiNP (10SiNP, 50SiNP, 150SiNP and 500SiNP) at different concentrations (1 to 200 μg/mL).
Platelets were incubated for 2 minutes at 37°C in a whole blood/optical lumi-aggregometer (model 700; Chrono-Log, Manchester, UK) prior to the addition of nanoparticles to test spontaneous aggregation. Platelet aggregation was studied for 15 minutes against blanks (Tyrode’s salt solution) containing the same particle concentration as the test tubes. Collagen was used as a positive control for platelet aggregation studies. Aggregation data was analyzed by Chrono-Log AGGRO-LINK 8 sofware.17–19
Selective platelet aggregation inhibitors (acetylsalicylic acid [ASA], phenanthroline, and apyrase) were added to test tubes. After 1 minute, SiNP were added to the appropriate test tubes.
Platelet aggregation was terminated at 30% maximal response, as determined using an aggregometer, in platelets exposed to 10 μg/mL 10SiNP. Unstimulated (resting) platelets were also prepared. Samples were fixed by mixing them with an equal volume of 3% glutaraldehyde in 0.1 M phosphate buffer for 1.5 hours at room temperature. After primary fixation, samples were centrifuged and pellets washed six times with phosphate buffer. Then, pellets were post-fixed with 2% osmium tetroxide in phosphate buffer for 30 minutes. Pellets were then dehydrated in a series of graded ethanol solution, infiltrated and embedded in agar 100 epoxy resin, using propylene oxide as a transitional fluid. Next, ultrathin sections were cut from dried blocks with a diatom diamond knife on a LKB ULTRATOM III (LKB, Uppsala, Sweden), stained with 0.5% aqueous uranyl acetate followed by Reynold’s lead citrate. Finally, sections were examined by a JEM 2100 transmission electron microscope.
Concurrent NO and ONOO− measurements were performed with electrochemical nanosensors (diameter: 300–500 nm). The designs are based on previously developed and well-characterized chemically modified carbon-fiber technology. 20,21 Each of the sensors was made by depositing a sensing material on the tip of the carbon fiber: conductive film of polymeric nickel (II) tetrakis (3-methoxy-4hydroxyphenyl) porphyrinic for the NO sensor20 and a polymeric film of Mn (III)–paracyclophanyl-porphyrin for the ONOO− sensor22. Amperometry was used to measure changes in NO and ONOO− concentrations from its basal level with time (detection limit of 1 nM and resolution time <10 μs for each sensor). Linear calibration curves were constructed for each sensor from 5 nM to 3 μM before and after measurements with aliquots of NO and ONOO− standard solutions, respectively. Measurements were performed into platelet suspensions. We tested the effect of different SiNP (10SiNP, 50SiNP, 150SiNP, and 500SiNP) at different concentrations (1 to 200 μg/mL).
Flow cytometry was performed using a FACSArray™ bioanalyzer (Becton, Dickinson and company [BD], Oxford, UK) on single stained platelet samples as described previously.17,23 Briefly, to analyze SELP expression, platelet aggregation was terminated at 30% maximal response, as determined using an aggregometer, in platelet exposed to different SiNP (10SiNP, 50SiNP, 150SiNP, and 500SiNP) at different concentrations (1 to 200 μg/mL). Platelet suspensions and anti-selectin-P antibody (BD) were then mixed and incubated in the dark at room temperature for 5 minutes. Platelets were identified by forward and side scatter signals, and 10,000 platelet-specific events were analyzed by the flow cytometer for fluorescence.
To analyze GPIIb/IIIa activation, platelet aggregation was terminated at 30% maximal response, as determined using an aggregometer, in platelets exposed to different SiNP as above. Platelet suspensions and PAC-1 antibody (BD) were mixed and incubated in the dark at room temperature for 15 minutes. Afterwards, an APC Rat Anti-Mouse IgM (secondary antibody) was added and samples incubated in the dark at room temperature for another 15 minutes. Platelets were identified by forward and side scatter signals, and 10,000 platelet-specific events were analyzed by the flow cytometer for fluorescence.
Nonactivated and activated platelets were gated so as not to analyze platelet aggregates. Silica nanoparticles were not detected by the bioanalyzer.
All data are presented as group of means ± standard error of the mean of n > 3. Statistical analysis of the mean difference between multiple groups was determined by one-way ANOVA followed by Tukey-Kramer multiple comparison tests; and between two groups by two-tailed Student’s t-tests. The alpha level for all tests was 0.05. A P value < 0.05 was considered to be statistically significant. All statistical analyses were performed using GraphPad Prism (version 5.00 for Windows; GraphPad Software, San Diego, CA) and Origin (version 6.1 for Windows; OriginLab, Northampton, MA).
In order to confirm the commercially-provided nanoparticle size, we used TEM to measure the size of SiNP. The TEM analysis of 10SiNP, 50SiNP, 150SiNP, and 500SiNP resulted in sizes of 10.50 ± 0.19 nm, 52.67 ± 0.66 nm, 148.20 ± 2.19 nm, and 495.90 ± 5.87 nm, respectively.1 Furthermore, Zetasizer reported high negative zeta potentials (more negative than −30 mV) for all SiNP tested in ultrapure water.1
We studied nanoparticle–platelet interactions and uptake using TEM (Figure 1). Electron micrographs showed amorphous SiNP forming agglomerates. These agglomerates were located within platelet aggregates, dispersed among platelets and interacting with the plasma membrane (Figure 1B–D). Nanoparticles also internalized and distributed into the platelet cytoplasm (Figure 1C and D). We also observed degranulated platelets indicating platelet activation (Figure 1C and D).
Using electrochemical nanosensors, we examined in situ, real-time dynamic interaction of amorphous SiNP with human platelets by measuring directly NO and ONOO− concentrations in a platelet suspension. We demonstrated with time resolution better than 10 μs that after collision with platelets, these nanoparticles rapidly stimulated NO release (Figure 2B) followed by a greater production of ONOO−. An increased ONOO− production was observed when nanoparticle concentration was increased and size decreased (Figure 2C). The exposure of human platelets to SiNP induced an unfavorable shift of the ratio of [NO]/[ONOO−], as nanoparticle size decreased. Indeed, 10 μg/mL 10SiNP induced a greater decrease in [NO]/[ONOO−] than an equal concentration of 50SiNP (Figure 2D). Moreover, 50SiNP (100 μg/mL) induced a lower ratio than an equal concentration of larger nanoparticles (Figure 2E).
We studied the ability of SiNP to induce platelet aggregation. Our results demonstrate that amorphous SiNP induce activation of GPIIb/IIIa as well as expression of SELP in the platelet surface membrane (Figure 3A and B). Importantly, platelet receptor activation and expression was inversely proportional to nanoparticle size and directly proportional to particle concentration. Indeed, the smallest nanoparticles (10SiNP) induced GPIIb/IIIa activation and SELP expression when used at a low concentration (10 μg/mL). In contrast, an equal concentration of larger nanoparticles (50SiNP, 150SiNP, and 500SiNP) did not influence platelet receptors. However, when used at a high concentration (100 μg/mL), 50SiNP induced both GPIIb/IIIa activation and SELP expression. Moreover, 200 μg/mL 150SiNP and 500SiNP induced SELP expression.
Furthermore, we demonstrated that amorphous SiNP directly induce platelet aggregation and that this effect is greater when nanoparticle size decreases and particle concentration increases (Figure 3C). Indeed, 10SiNP induced platelet aggregation when used at a concentration of 10 μg/mL or higher. Also, 50SiNP and 150SiNP induced platelet aggregation when used at a concentration of 100 μg/mL and 200 μg/mL, respectively. However, 500SiNP did not induce platelet aggregation even when used at a very high concentration of 200 μg/mL.
Knowing that 10SiNP at 10 μg/mL were able to induce platelet aggregation, further experiments with selective inhibitors of the pathways leading to platelet aggregation mediated by TXA2 (ASA), ADP (apyrase), and MMP2 (phenanthroline) were carried out to characterize the mechanism of SiNP-induced platelet aggregation (Figure 3D). Our results show that incubation of platelets with both phenanthroline and apyrase, but not ASA, prior to their exposure to nanoparticles, inhibited nanoparticle-induced platelet aggregation (Figures 3D and 4).
Platelets and endothelial cells are crucial for the correct maintenance of vascular homeostasis. To exert their function, platelets survey the vascular system and adhere where alterations of the endothelial cell lining, accompanied or not by exposure of subendothelial matrix components, are detected.24 On the other hand, by the secretion or surface expression of a series of specific molecules (NO, prostacyclin), endothelial cells ensure that under normal conditions blood flow is appropriately regulated and that intravascular platelet activation and blood coagulation are avoided.
The deleterious effect of SiNP on endothelial cells found in our previous work1 prompted us therefore to study the effect of SiNP on human platelets. In this current study, we found that amorphous SiNP when interacting with human blood platelets have the ability to stimulate the release of NO and to a greater extent ONOO− leading to a low [NO]/[ONOO−] ratio that correlated well with the SiNP-induced platelet aggregation. Indeed, we observed that SiNP stimulated GPIIb/IIIa activation and SELP expression and led to platelet aggregation via ADP- and MMP2-dependent mechanisms. All of these effects augmented with increased nanoparticle concentration, but were inversely proportional to the size of SiNP. In fact, the smallest SiNP (10 nm) induced the most severe effects on platelets. Recently, our studies on the effects of amorphous SiNP on human endothelial cells also reported the role of the [NO]/[ONOO−] ratio in the nanoparticle-induced endothelial inflammatory and cytotoxic responses.1
Amorphous SiNP have a noncrystalline structure, a high surface-area-to-volume ratio and a large negative surface charge. A high surface-area-to-volume ratio, which decreases in the opposite direction to size, favors the formation of the “protein corona” with fundamental significance for bionanointeractions. The “protein corona” along with fluid characteristics and particle surface area and zeta potentials can affect the formation of nanoparticle agglomerates in the biological environment and may influence nanoparticle toxicity.25,26
Our TEM study shows that SiNP interacted with the platelet surface membrane, internalized and distributed within the platelet cytoplasm. The interaction of SiNP with platelet surface membranes raised the possibility that nanoparticles can affect calcium channels as well as the endothelial nitric oxide synthase (eNOS) that is associated with caveolae.27 Indeed, there is convincing evidence that modulation of mechanosensitive ion channels involves NO and ONOO−.28 Therefore, we hypothesized that amorphous SiNP collide with the platelet surface membrane leading to opening of calcium channels, and eventually, uncoupling of eNOS. The kinetics of the penetration of the platelet membrane by SiNP most likely involved a flux of calcium ions into the cytoplasm.29 Therefore, SiNP are likely to stimulate a calcium-dependent NO release in human platelets. The process of increased and prolonged NO production leads to depletion of enzymatic substrates and cofactors, and eventually, uncoupling of eNOS.30 The uncoupled eNOS can generate superoxide10 which can rapidly react with NO to produce ONOO− and change critically the balance of [NO]/[ONOO−]. At high level of cytoprotective NO and/or low level of cytotoxic ONOO−, this ratio is high (>2.0) indicating coupled eNOS and normal endothelial and platelet function. A low ratio (<1.0) is associated with uncoupled eNOS, dysfunctional cardiovascular system and high nitroxidative/oxidative stress.1,9,10 Our current experimental results support this hypothesis and show that amorphous SiNP unfavorably shift the [NO]/[ONOO−] balance to low levels. There is convincing evidence that platelet aggregation is favored by nitroxidative/oxidative stress induced by ONOO−.11,12 Indeed, platelet-derived and exogenous ONOO− induce TXA2 formation,31 nitration of tyrosine-containing proteins,32 SELP expression and GPIIb/IIIa activation.12 The activation of GPIIb/IIIa (a change from the low- to high-affinity conformation) and translocation of SELP to the platelet surface membrane is crucial for platelet aggregation to occur.33,34 Indeed, GPIIb/IIIa is the major platelet surface transmembrane receptor and it plays an important role in platelet aggregation. 35 In addition, platelets contain a pool of this glycoprotein stored in α-granules.36 Furthermore, SELP, that is also stored in platelet α-granules, mediates platelet-leukocyte aggregation since it is rapidly translocated to the surface upon platelet activation.37 Our studies demonstrate that SiNP have the ability to induce GPIIb/IIIa activation and SELP expression on the platelet surface membrane leading to platelet aggregation. Interestingly, carbon nanoparticles, including nanotubes, have a similar ability.38,39 The activation of GPIIb/IIIa is triggered off by the release of major platelet activators that mediate pathways of aggregation such as TXA2,13 ADP,14 and MMP215 which amplify aggregation. In fact, we have previously shown that MMP2 translocates to the platelet surface during platelet aggregation.40 Indeed, it has been also demonstrated the interaction of MMP2 with the integrin αIIβIII on the platelet membrane. 41 We demonstrate here that SiNP can stimulate platelet aggregation via ADP- and MMP2-dependent mechanisms. However, in contrast to agonist-induced aggregation which can be abolished by combination of ASA, apyrase, and phenanthroline,15 SiNP-induced aggregation is not completely dependent on the release of TXA2, ADP, and MMP2. Interestingly, nanoparticles can directly interact with proteins and ion channels and these effects can also contribute to the profile of SiNP actions on platelets.42,43
In conclusion, engineered amorphous SiNP penetrated the platelet plasma membrane and stimulated a rapid and prolonged NO release leading to eNOS uncoupling, ONOO− over- production and eventually, a low [NO]/[ONOO−] ratio and high nitroxidative/oxidative stress. The unfavorable situation, thus produced, favored receptors activation (GPIIb/IIIa) and expression (SELP) on the platelet surface membrane leading to platelet activation and aggregation. Furthermore, SiNP-induced platelet aggregation is mediated via the MMP2 and ADP pathways. Importantly, these effects were all inversely proportional to the amorphous SiNP size and directly proportional to nanoparticle concentration. These findings, along with our study on endothelial cells,1 conclusively highlight the importance of NO/peroxynitrite imbalance in the pathomechanism of nanotoxicological effects of amorphous SiNP with profound implications in the disruption of vascular homeostasis.
The authors report no conflicts of interest in this work.
This project was funded by a Science Foundation Ireland grant to MWR and a Trinity College Dublin award to JJC. Authors would like to thank Dr Lorraine O’Driscoll, Dr Lidia Tajber, Dr Maria Jose Santos-Martinez, Dr Alan Gaffney, Mr Neal Leddy, Mr Dino Muravec and Ms Neasa Chambers for advice and technical assistance. CM is Science Foundation Ireland Stokes lecturer.
|1.||Corbalan JJ,Medina C,Jacoby A,Malinski T,Radomski MW. Amorphous silica nanoparticles trigger nitric oxide/peroxynitrite imbalance in human endothelial cells: inflammatory and cytotoxic effectsInt J NanomedicineYear: 201162821283522131828|
|2.||Radomski MW,Palmer RM,Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxideBr J PharmacolYear: 19879236396463322462|
|3.||Radomski MW,Palmer RM,Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregationProc Natl Acad Sci U S AYear: 19908713519351971695013|
|4.||Palmer RM,Ferrige AG,Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factorNatureYear: 198732761225245263495737|
|5.||Malinski T,Radomski MW,Taha Z,Moncada S. Direct electrochemical measurement of nitric oxide released from human plateletsBiochem Biophys Res CommunYear: 199319429609658343175|
|6.||Pacher P,Beckman JS,Liaudet L. Nitric oxide and peroxynitrite in health and diseasePhysiol RevYear: 200787131542417237348|
|7.||Alonso D,Radomski MW. Nitric oxide, platelet function, myocardial infarction and reperfusion therapiesHeart Fail RevYear: 200381475412652159|
|8.||Poyton RO,Ball KA,Castello PR. Mitochondrial generation of free radicals and hypoxic signalingTrends Endocrinol MetabYear: 200920733234019733481|
|9.||Heeba G,Hassan MK,Khalifa M,Malinski T. Adverse balance of nitric oxide/peroxynitrite in the dysfunctional endothelium can be reversed by statinsJ Cardiovasc PharmacolYear: 200750439139818049306|
|10.||Kalinowski L,Dobrucki IT,Malinski T. Race-specific differences in endothelial function: predisposition of African Americans to vascular diseasesCirculationYear: 2004109212511251715159296|
|11.||Villa LM,Salas E,Darley-Usmar VM,Radomski MW,Moncada S. Peroxynitrite induces both vasodilatation and impaired vascular relaxation in the isolated perfused rat heartProc Natl Acad Sci U S AYear: 1994912612383123877809045|
|12.||Moro MA,Darley-Usmar VM,Goodwin DA,et al. Paradoxical fate and biological action of peroxynitrite on human plateletsProc Natl Acad Sci U S AYear: 19949114670267067517561|
|13.||Needleman P,Moncada S,Bunting S,Vane JR,Hamberg M,Samuelsson B. Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxidesNatureYear: 19762615561558560934294|
|14.||Born GV. Effects of adenosine diphosphate (ADP) and related substances on the adhesiveness of platelets in vitro and in vivoBr J HaematolYear: 196612137385906266|
|15.||Sawicki G,Salas E,Murat J,Miszta-Lane H,Radomski MW. Release of gelatinase A during platelet activation mediates aggregationNatureYear: 199738666256166199121586|
|16.||Radomski M,Moncada S. An improved method for washing of human platelets with prostacyclinThromb ResYear: 19833043833896351341|
|17.||Radomski A,Stewart MW,Jurasz P,Radomski MW. Pharmacological characteristics of solid-phase von Willebrand factor in human plateletsBr J PharmacolYear: 200113451013102011682449|
|18.||Radomski A,Jurasz P,Sanders EJ,et al. Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human plateletsBr J PharmacolYear: 200213781330133812466243|
|19.||Jurasz P,Alonso D,Castro-Blanco S,Murad F,Radomski MW. Generation and role of angiostatin in human plateletsBloodYear: 200310293217322312855585|
|20.||Malinski T,Taha Z. Nitric oxide release from a single cell measured in situ by a porphyrinic-based microsensorNatureYear: 199235863886766781495562|
|21.||Brovkovych V,Patton S,Brovkovych S,Kiechle F,Huk I,Malinski T. In situ measurement of nitric oxide, superoxide and peroxynitrite during endotoxemiaJ Physiol PharmacolYear: 19974846336449444612|
|22.||Kalinowski L,Malinski T. Endothelial NADH/NADPH- dependent enzymatic sources of superoxide production: relationship to endothelial dysfunctionActa Biochim PolYear: 200451245946915218542|
|23.||Jurasz P,Stewart MW,Radomski A,Khadour F,Duszyk M,Radomski MW. Role of von Willebrand factor in tumour cell-induced platelet aggregation: differential regulation by NO and prostacyclinBr J PharmacolYear: 200113451104111211682459|
|24.||Ruggeri ZM,Mendolicchio GL. Adhesion mechanisms in platelet functionCirc ResYear: 2007100121673168517585075|
|25.||Lundqvist M,Stigler J,Elia G,Lynch I,Cedervall T,Dawson KA. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impactsProc Natl Acad Sci U S AYear: 200810538142651427018809927|
|26.||Thomassen LC,Aerts A,Rabolli V,et al. Synthesis and characterization of stable monodisperse silica nanoparticle sols for in vitro cytotoxicity testingLangmuirYear: 201026132833519697952|
|27.||Nishikawa T,Iwakiri N,Kaneko Y,et al. Nitric oxide release in human aortic endothelial cells mediated by delivery of amphiphilic polysiloxane nanoparticles to caveolaeBiomacromoleculesYear: 20091082074208519583242|
|28.||Dyachenko V,Rueckschloss U,Isenberg G. Modulation of cardiac mechanosensitive ion channels involves superoxide, nitric oxide and peroxynitriteCell CalciumYear: 2009451556418639930|
|29.||Gelderman MP,Simakova O,Clogston JD,et al. Adverse effects of fullerenes on endothelial cells: fullerenol C60(OH)24 induced tissue factor and ICAM-I membrane expression and apoptosis in vitroInt J NanomedicineYear: 200831596818488416|
|30.||Huk I,Nanobashvili J,Neumayer C,et al. L-arginine treatment alters the kinetics of nitric oxide and superoxide release and reduces ischemia/reperfusion injury in skeletal muscleCirculationYear: 19979626676759244241|
|31.||Schildknecht S,van der Loo B,Weber K,Tiefenthaler K,Daiber A,Bachschmid MM. Endogenous peroxynitrite modulates PGHS-1- dependent thromboxane A2 formation and aggregation in human plateletsFree Radic Biol MedYear: 200845451252018514074|
|32.||Naseem KM,Khan J,Jacobs M,Bruckdorfer KR. Nitration of platelet cytosolic proteins by peroxynitriteBiochem Soc TransYear: 1997253397S9388627|
|33.||Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategyCirculationYear: 1995929237323807586333|
|34.||Radomski MW,Radomski AS. Regulation of blood cell function by the endothelial cellsVallance PJT,Wallance DJVascular Endothelium in Human Physiology and PathophysiologyLondon, UKHarwood Academic PublishersYear: 200095106|
|35.||Shattil SJ,Kashiwagi H,Pampori N. Integrin signaling: the platelet paradigmBloodYear: 1998918264526579531572|
|36.||Wagner CL,Mascelli MA,Neblock DS,Weisman HF,Coller BS,Jordan RE. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human plateletsBloodYear: 19968839079148704248|
|37.||Andrews RK,Berndt MC. Platelet physiology and thrombosisThromb ResYear: 20041145–644745315507277|
|38.||Radomski A,Jurasz P,Alonso-Escolano D,et al. Nanoparticle-induced platelet aggregation and vascular thrombosisBr J PharmacolYear: 2005146688289316158070|
|39.||Bihari P,Holzer M,Praetner M,et al. Single-walled carbon nanotubes activate platelets and accelerate thrombus formation in the microcirculationToxicologyYear: 20102692–314815419698757|
|40.||Sawicki G,Sanders EJ,Salas E,Wozniak M,Rodrigo J,Radomski MW. Localization and translocation of MMP-2 during aggregation of human plateletsThromb HaemostYear: 19988058368399843180|
|41.||Choi WS,Jeon OH,Kim HH,Kim DS. MMP-2 regulates human platelet activation by interacting with integrin alphaIIbbeta3J Thromb HaemostYear: 20086351752318088350|
|42.||McCarthy J,Gong X,Nahirney D,Duszyk M,Radomski M. Polystyrene nanoparticles activate ion transport in human airway epithelial cellsInt J NanomedicineYear: 201161343135621760729|
|43.||Cedervall T,Lynch I,Lindman S,et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticlesProc Natl Acad Sci U S AYear: 200710472050205517267609|
Keywords: amorphous silica nanoparticles, nanotoxicology, nitric oxide, peroxynitrite, platelet aggregation.
Previous Document: Synthesis, characterization, and in vivo efficacy evaluation of PGG-docetaxel conjugate for potentia...
Next Document: Analysis of in situ and ex vivo ?V?3 integrin expression during experimental carotid atherogenesis.